Jurga Bernatoniene

Berotralstat was well-tolerated and seemed to durably reduce hereditary angioedema (HAE) attacks, in findings from the APeX-P open-label study. Data from the study were presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California, by Jurga Bernatoniene, PhD, professor, Lithuanian University of Health Sciences.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.